Document:

Exhibit 4.3

  

	
    NUMBER

    ________-
	 	
    (SEE REVERSE SIDE FOR LEGEND)

    THIS WARRANT WILL BE VOID IF NOT EXERCISED PRIOR
    TO THE EXPIRATION DATE (DEFINED BELOW)
	 	WARRANTS

 

LARKSPUR HEALTH ACQUISITION CORP.

CUSIP [_]

WARRANT 

 

THIS CERTIFIES THAT, for value received

 

is the registered holder of a warrant or warrants
(the “Warrant”) of Larkspur Health Acquisition Corp., a Delaware corporation (the “Company”), expiring
at 5:00 p.m., New York City time, on the five year anniversary of the Company’s completion of an initial business combination, capital
stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or
entities (a “Business Combination”), or earlier upon redemption or liquidation, to purchase one fully paid and non-assessable
share of common stock, par value $0.0001 per share (“Shares”), of the Company for each Warrant evidenced by this Warrant
Certificate. The Warrant entitles the holder thereof to purchase from the Company, commencing on the later of the Company’s completion
of an initial Business Combination and twelve (12) months from the closing of the Company’s initial public offering, such number
of Shares of the Company at the Warrant Price (as defined below), upon surrender of this Warrant Certificate and payment of the Warrant
Price at the office or agency of Continental Stock Transfer & Trust Company (the “Warrant Agent”), but only subject
to the conditions set forth herein and in the Warrant Agreement between the Company and Warrant Agent. In no event will the Company be
required to net cash settle any warrant exercise. The Warrant Agreement provides that upon the occurrence of certain events the Warrant
Price and the number of Shares purchasable hereunder, set forth on the face hereof, may, subject to certain conditions, be adjusted. The
term “Warrant Price” as used in this Warrant Certificate refers to the price per Share at which Shares may be purchased
at the time the Warrant is exercised. The initial Warrant Price per Share for any Warrant is equal to $11.50 per share.

 

No fraction of a Share will
be issued upon any exercise of a Warrant. If the holder of a Warrant would be entitled to receive a fraction of a Share upon any exercise
of a Warrant, the Company shall, upon such exercise, round down to the nearest whole number the number of Shares to be issued to such
holder.

 

Upon any exercise of the
Warrant for less than the total number of full Shares provided for herein, there shall be issued to the registered holder hereof or the
registered holder’s assignee a new Warrant Certificate covering the number of Shares for which the Warrant has not been exercised.

 

Warrant Certificates, when
surrendered at the office or agency of the Warrant Agent by the registered holder in person or by attorney duly authorized in writing,
may be exchanged in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge,
for another Warrant Certificate or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants.

 

Upon due presentment for
registration of transfer of the Warrant Certificate at the office or agency of the Warrant Agent, a new Warrant Certificate or Warrant
Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee in exchange for
this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any applicable tax or
other governmental charge.

 

The Company and the Warrant
Agent may deem and treat the registered holder as the absolute owner of this Warrant Certificate (notwithstanding any notation of ownership
or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the registered holder, and for
all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

 

     

     

    

 

This Warrant does not entitle
the registered holder to any of the rights of a shareholder of the Company.

 

The Company reserves the
right to call the Warrant at any time prior to its exercise with a notice of call in writing to the holders of record of the Warrant,
giving at least 30 days’ notice of such call, at any time while the Warrant is exercisable, if the last sale price of the Shares
has been at least $18.00 per share (the “Redemption Trigger Price”) on each of 20 trading days within any 30 trading day period
(the “30-day trading period”) ending on the third business day prior to the date on which notice of such call is given
and if, and only if, there is a current registration statement in effect with respect to the Shares underlying the Warrants for the entire
30-day trading period and continuing each day thereafter until the date of redemption. The call price of the Warrants is to be $0.01 per
Warrant. Any Warrant either not exercised or tendered back to the Company by the end of the date specified in the notice of call shall
be canceled on the books of the Company and have no further value except for the $0.01 call price.

 

	By	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	President	 	 	Secretary

 

SUBSCRIPTION FORM

 

To Be Executed by the Registered Holder in Order
to Exercise Warrants

 

The undersigned Registered Holder irrevocably elects to exercise ______________ Warrants
represented by this Warrant Certificate, and to purchase the shares of common stock of the Company issuable upon the exercise of such
Warrants, and requests that Certificates for such shares shall be issued in the name of

 

	 
	(PLEASE TYPE OR PRINT NAME AND ADDRESS)
	 
	 
	 

(SOCIAL SECURITY OR TAX IDENTIFICATION NUMBER)

	and be delivered to 	 

(PLEASE PRINT OR TYPE NAME AND ADDRESS)

 

and, if such number of Warrants shall not be all the Warrants evidenced
by this Warrant Certificate, that a new Warrant Certificate for the balance of such Warrants be registered in the name of, and delivered
to, the Registered Holder at the address stated below:

 

	Dated: 	 	 	 
	 	(SIGNATURE)
	 	 
	 	(ADDRESS)
	 	 
	 	 
	 	 
	 	(TAX IDENTIFICATION NUMBER)

 

    2

     

    

 

ASSIGNMENT

 

To Be Executed by the Registered Holder in Order
to Assign Warrants

 

For Value Received, _______________________ hereby sell, assign, and
transfer unto

 

	 
	(PLEASE TYPE OR PRINT NAME AND ADDRESS)
	 
	 
	 

(SOCIAL SECURITY OR TAX IDENTIFICATION NUMBER)

	and be delivered to 	 

(PLEASE PRINT OR TYPE NAME AND ADDRESS)

 

______________________ of the Warrants represented by this Warrant
Certificate, and hereby irrevocably constitute and appoint _________________________________ Attorney to transfer this Warrant Certificate
on the books of the Company, with full power of substitution in the premises.

 

	Dated: 	 	 	 
	 	(SIGNATURE)

 

The signature to the assignment
of the Subscription Form must correspond to the name written upon the face of this Warrant Certificate in every particular, without alteration
or enlargement or any change whatsoever, and must be guaranteed by a commercial bank or trust company or a member firm of the NYSE American,
Nasdaq, New York Stock Exchange, Pacific Stock Exchange, or Chicago Stock Exchange.

 

 

3Exhibit
10.1

 

[__],
2021

 

Larkspur
Health Acquisition Corp.

100 Somerset
Corporate Blvd., 2nd Floor

Bridgewater,
NJ 08807

 

	Re:	Initial
    Public Offering 

 

Ladies
and Gentlemen:

 

This
letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting
Agreement (the “Underwriting Agreement”) entered into by and among Larkspur Health Acquisition Corp.,
a Delaware corporation (the “Company”), and A.G.P./Alliance Global Partners, as representative (the “Representative”)
of the several underwriters (each, an “Underwriter” and collectively, the “Underwriters”),
relating to an underwritten initial public offering (the “Public Offering”), of 7,500,000 of
the Company’s units (including up to 1,125,000 units that may be purchased to cover over-allotments, if any) (the “Units”),
each comprised of one share of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”),
and one-half of one redeemable warrant (the “Warrant”). Each whole Warrant entitles the holder thereof to purchase
one share of Common Stock at a price of $11.50 per share, subject to adjustment. The Units will be sold in the Public Offering pursuant
to a registration statement on Form S-1 (File No. 333-256056) and prospectus (the “Prospectus”) filed
by the Company with the U.S. Securities and Exchange Commission (the “Commission”) and the Company has applied
to have the Units listed on The Nasdaq Global Market. Certain capitalized terms used herein are defined in paragraph 12 hereof.

 

In
order to induce the Company and the Underwriters to enter into the Underwriting Agreement and to proceed with the Public Offering and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of Larkspur Health LLC
(the “Sponsor”) and the undersigned individuals, each of whom is a member of the Company’s board of directors
and/or management team or an advisor of the Company (other than the Representative) (each, an “Insider” and
collectively, the “Insiders”), and the Representative hereby agrees with the Company as follows:

 

1.
The Sponsor, the Representative, and each Insider agrees that if the Company seeks stockholder approval of a proposed Business Combination,
then in connection with such proposed Business Combination, it, he or she shall (i) vote any shares of Capital Stock owned by it,
him or her in favor of any proposed Business Combination and (ii) not redeem any shares of Capital Stock owned by it, him or her
in connection with such stockholder approval. If the Company engages in a tender offer in connection with any proposed Business Combination,
the Sponsor, and each Insider agrees that it, he or she will not seek to sell or tender any shares of Capital Stock owned by it, him
or her to the Company in connection with such tender offer.

 

2.
The Sponsor and each Insider hereby agrees that in the event that the Company fails to consummate a Business Combination 24 months from
the closing of the Public Offering, or such later period approved by the Company’s stockholders in accordance with the Company’s
amended and restated certificate of incorporation (as it may be amended from time to time, the “Charter”),
the Sponsor and each Insider shall take all reasonable steps to cause the Company to (i) cease all operations except for the purpose
of winding up, (ii) as promptly as reasonably possible but not more than 10 business days thereafter, subject to lawfully available
funds therefor, redeem 100% of the shares of Common Stock sold as part of the Units in the Public Offering (the “Offering Shares”),
at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account (as defined below), including
interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (as described in the
Prospectus) (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Offering Shares,
which redemption will completely extinguish the rights of all holders of Offering Shares as stockholders (including the right to receive
further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such
redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve
and liquidate, subject in the case of clauses (ii) and (iii) to the Company’s obligations under Delaware law to provide
for claims of creditors and the requirements of other applicable law. The Sponsor and each Insider agrees not to propose any amendment
to the Charter to modify (i) the substance or timing of the ability of holders of Offering Shares to seek redemption in connection
with the Company’s initial Business Combination or amendments to the Charter prior thereto or (ii) (A) the Company’s
obligation to redeem 100% of the Offering Shares if the Company does not complete its initial Business Combination within such time set
forth in the Charter or (B) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination
activity, unless the Company provides the holders of the Offering Shares with the opportunity to redeem their shares of Common Stock
upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes
(as described in the Prospectus), divided by the number of then outstanding Offering Shares.

 

     

    

    

 

The
Sponsor, the Representative, and each Insider acknowledges that it, he or she has no right, title, interest or claim of any kind in or
to any monies held in the Trust Account or any other asset of the Company as a result of any liquidation of the Company with respect
to the Founder Shares or Private Placement Shares held by it, him or her. The Sponsor, the Representative, and each Insider hereby further
waives, with respect to any shares of Capital Stock held by it, him or her, if any, whether acquired now or hereafter, any redemption
rights it, he or she may have in connection with the consummation of a Business Combination or amendments to the Charter prior thereto,
including, without limitation, any such rights available in the context of a stockholder vote to approve such Business Combination or
a stockholder vote to approve an amendment to the Charter to modify (i) (A) the substance or timing of the Company’s
obligation to redeem 100% of the Offering Shares if the Company has not consummated a Business Combination within the time period set
forth in the Charter or (B) any other provisions relating to stockholders’ rights or pre-initial Business Combination activity
or (ii) in the context of a tender offer made by the Company to purchase shares of Common Stock (although the Sponsor, the Representative,
the Insiders and their respective affiliates shall be entitled to redemption and liquidation rights with respect to any Offering Shares
it or they hold if the Company fails to consummate a Business Combination within the time period set forth in the Charter).

 

3.
During the period commencing on the effective date of the Underwriting Agreement and ending 180 days after such date, the Sponsor and
each Insider shall not, without the prior written consent of the Representative, (i) sell, offer to sell, contract or agree to sell,
hypothecate, pledge, grant any option, right or warrant to purchase, lend, or otherwise dispose of or agree to dispose of, directly or
indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning
of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and
regulations of the Commission promulgated thereunder, with respect to any Units, shares of Capital Stock, Warrants or any securities
convertible into, or exercisable, or exchangeable for, shares of Capital Stock owned by it, him or her, (ii) enter into any swap
or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Units, shares
of Capital Stock, Warrants or any securities convertible into, or exercisable, or exchangeable for, shares of Capital Stock owned by
it, him or her, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, (iii) file or caused
to be filed any registration statement with the Commission relating to the offering of any Units, shares of Capital Stock, Warrants or
any securities convertible into, or exercisable, or exchangeable for, shares of Common Stock owned by it, him or her, (iv) complete any
offering of debt securities of the Company, other than entering into a line of credit with a traditional bank, or (v) publicly announce
any intention to effect any transaction specified in clause (i), (ii), (iii) or (iv). Each of the Insiders and the Sponsor acknowledges
and agrees that, prior to the effective date of any release or waiver, of the restrictions set forth in this paragraph 3 or paragraph
7 below, the Company shall announce the impending release or waiver by press release through a major news service at least two business
days before the effective date of the release or waiver. Any release or waiver granted shall only be effective two business days after
the publication date of such press release. The provisions of this paragraph will not apply if the release or waiver is effected solely
to permit a transfer not for consideration and the transferee has agreed in writing to be bound by the same terms described in this Letter
Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer.

 

4.
In the event of the liquidation of the Trust Account upon the failure of the Company to consummate its initial Business Combination within
the time period set forth in the Charter, the Sponsor (the “Indemnitor”) agrees to indemnify and hold harmless
the Company against any and all loss, liability, claim, damage and expense whatsoever (including, but not limited to, any and all legal
or other expenses reasonably incurred in investigating, preparing or defending against any litigation, whether pending or threatened)
to which the Company may become subject as a result of any claim by (i) any third party for services rendered or products sold to
the Company or (ii) any prospective target business with which the Company has entered into a written letter of intent, confidentiality
or other similar agreement or Business Combination agreement (a “Target”); provided, however, that
such indemnification of the Company by the Indemnitor shall (x) apply only to the extent necessary to ensure that such claims by
a third party or a Target do not reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Offering
Share and (ii) the actual amount per Offering Share held in the Trust Account as of the date of the liquidation of the Trust Account,
if less than $10.00 per Offering Share is then held in the Trust Account due to reductions in the value of the trust assets, less interest
earned on the Trust Account which may be withdrawn to pay taxes, (y) not apply to any claims by a third party or a Target which
executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) and (z) not
apply to any claims under the Company’s indemnity of the Underwriters against certain liabilities, including liabilities under
the Securities Act of 1933, as amended. The Indemnitor shall have the right to defend against any such claim with counsel of its choice
reasonably satisfactory to the Company if, within 15 days following written receipt of notice of the claim to the Indemnitor, the Indemnitor
notifies the Company in writing that it shall undertake such defense.

 

5.
To the extent that the Underwriters do not exercise their over-allotment option to purchase up to an additional 1,125,000 Units within
45 days from the date of the Prospectus (and as further described in the Prospectus), the Sponsor, the Representative, and each Insider
agree to forfeit, in proportion to their respective percentage ownership of the total Founder Shares, at no cost, a number of Founder
Shares in the aggregate equal to 259,473 multiplied by a fraction, (i) the numerator of which is 1,250,000 minus the number of Units
purchased by the Underwriters upon the exercise of their over-allotment option, and (ii) the denominator of which is 1,125,000.
The forfeiture will be adjusted to the extent that the over-allotment option is not exercised in full by the Underwriters so that the
Sponsor, the Representative, and each Insider will be required to forfeit only that number of Founder Shares as is necessary so that
the Initial Stockholders will own an aggregate of 20.0% of the Company’s issued and outstanding shares of Capital Stock after the
Public Offering (excluding the shares underlying the Private Placement Warrants).

 

    2

    

    

 

6.
(a) The Sponsor and the Insiders hereby agree not to participate in the formation of, or become an officer or director of, any
special purpose acquisition company with a class of securities registered under the Exchange Act, other than the Company, until the
Company has entered into a definitive agreement regarding an initial Business Combination or the Company has failed to complete an
initial Business Combination within 24 months after the closing of the Public Offering, as such period may be extended by Company
stockholder approval.

 

(b)
The Sponsor and each Insider hereby agrees and acknowledges that: (i) the Underwriters and the Company would be irreparably injured
in the event of a breach by such Sponsor or an Insider of its, his or her obligations under paragraphs 1, 2, 3, 4, 5, 7(a), 7(b), 8 and
10, as applicable, of this Letter Agreement (ii) monetary damages may not be an adequate remedy for such breach and (iii) the
non-breaching party shall be entitled to injunctive relief, in addition to any other remedy that such party may have in law or in equity,
in the event of such breach.

 

7.
(a) The Sponsor, the Representative, and each Insider agrees that it, he or she shall not Transfer any Founder Shares (or shares
of Common Stock issuable upon conversion thereof) until the earlier to occur of (A) 180 days after the completion of the Company’s
initial Business Combination and (B) subsequent to the Company’s initial Business Combination, (x) if the reported last
sale price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations
and the like) for any 20 trading days within any 30-trading day period commencing at least 90 days after the Company’s initial
Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization
or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of Common
Stock for cash, securities or other property (the “Founder Shares Lock-up Period”).

 

(b) The
Sponsor and each Insider agrees that it, he or she shall not Transfer any Private Placement Units, the Private Placement Shares, the
Private Placement Warrants or shares of Common Stock issued or issuable upon the exercise of the Private Placement Warrants, until after
the completion of the initial Business Combination (the “Private Placement Units Lock-up Period”,
together with the Founder Shares Lock-up Period, the “Lock-up Periods”).

 

(c) Notwithstanding
the provisions set forth in paragraphs 7(a) and 7(b), Transfers of the Founder Shares, Private Placement Units, Private Placement
Shares, Private Placement Warrants and shares of Common Stock issued or issuable upon the exercise or conversion of the Private Placement
Warrants or the Founder Shares that are held by the Sponsor, the Representative, or any Insider or any of their permitted transferees
(that have complied with this paragraph 7(c)), are permitted (i) to the Company’s officers or directors, any affiliates or
family members of any of the Company’s officers or directors, any members of the Sponsor, or any affiliates of the Sponsor, (ii) in
the case of an individual, by gift to a member of one of the members of the individual’s immediate family or to a trust, the beneficiary
of which is a member of one of the individual’s immediate family, an affiliate of such person or to a charitable organization;
(iii) in the case of an individual, by virtue of laws of descent and distribution upon death of any of the Company’s officers,
directors, the initial stockholders or members of the Sponsor; (iv) in the case of an individual, pursuant to a qualified domestic
relations order; (v) by private sales or transfers made in connection with the consummation of an initial business combination at
prices no greater than the price at which the securities were originally purchased; (vi) in the event of the Company’s liquidation
prior to the completion of the initial Business Combination; (vii) by virtue of the laws of Delaware or the Sponsor’s limited
liability company agreement upon dissolution of the Sponsor; or (viii) in the event of the Company’s liquidation, merger,
capital stock exchange, reorganization or other similar transaction which results in all of the Company’s stockholders having the
right to exchange their shares of Common Stock for cash, securities or other property subsequent to our completion of our initial business
combination; provided, however, that in the case of clauses (i) through (v) or (vii), these permitted
transferees must enter into a written agreement with the Company agreeing to be bound by the transfer restrictions herein and the other
restrictions contained in this Agreement (including provisions relating to voting, the Trust Account and liquidating distributions).

 

    3

    

    

 

8. The Sponsor and each Insider
shall offer all suitable Business Combination opportunities to the Company before any other person or company until the consummation
by the Company of a Business Combination, subject to any pre-existing contractual or fiduciary obligations they may have, (which pre-existing
fiduciary duties and any potential conflicts of interest arising there from shall be disclosed to the Representative prior to the initial
filing of the Prospectus and in the Prospectus itself), on customary terms reasonably acceptable to the Representative.

 

9.
The Sponsor and each Insider represents and warrants that it, he or she has never been suspended or expelled from membership in any securities
or commodities exchange or association or had a securities or commodities license or registration denied, suspended or revoked. Each
Insider’s biographical information furnished to the Company (including any such information included in the Prospectus) is true
and accurate in all respects and does not omit any material information with respect to the Insider’s background. Each Insider’s
questionnaire furnished to the Company is true and accurate in all respects. Each Insider represents and warrants that: it, he or she
is not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or
refrain from any act or practice relating to the offering of securities in any jurisdiction; it, he or she has never been convicted of,
or pleaded guilty to, any crime (i) involving fraud, (ii) relating to any financial transaction or handling of funds of another
person, or (iii) pertaining to any dealings in any securities and it, he or she is not currently a defendant in any such criminal
proceeding.

 

10.
Except as disclosed in the Prospectus, neither the Sponsor nor any officer or director of the Company nor any affiliate of the Sponsor
nor any affiliate of any officer or director of the Company, shall receive from the Company any finder’s fee, reimbursement, consulting
fee, monies in respect of any repayment of a loan or other compensation prior to, or in connection with any services rendered in order
to effectuate, the consummation of the Company’s initial Business Combination (regardless of the type of transaction that it is),
other than the following, none of which will be made from the proceeds held in the Trust Account prior to the completion of the initial
Business Combination: repayment of up to an aggregate of $750,000 in loans made to the Company by the Sponsor’s investors to cover
offering-related and organizational expenses; reimbursement for any reasonable out-of-pocket expenses related to identifying, investigating
and completing an initial Business Combination; and repayment of non-interest bearing loans which may be made by the Sponsor or an affiliate
of the Sponsor or certain of the Company’s officers and directors to finance transaction costs in connection with an intended initial
Business Combination, the terms of which (other than as described above) have not been determined nor have any written agreements been
executed with respect thereto.

 

11.
The Sponsor and each Insider has full right and power, without violating any agreement to which it is bound (including, without limitation,
any non-competition or non-solicitation agreement with any employer or former employer), to enter into this Letter Agreement and, as
applicable, to serve as an officer and/or director on the board of directors of the Company and hereby consents to being named in the
Prospectus as an officer and/or director of the Company.

 

    4

    

    

 

12.
As used herein, (i) “Business Combination” shall mean a merger, capital stock exchange,
asset acquisition, stock purchase, reorganization or similar business combination, involving the Company and one or more businesses;
(ii) “Capital Stock” shall mean, collectively, the Common Stock and the Founder Shares;
(iii) “Founder Shares” shall mean (a) the 2,134,473 shares of the Company’s
Class B common stock, par value $0.0001 per share, initially issued to the Initial Stockholders (up to 259,473 Shares of which are
subject to complete or partial forfeiture by the Initial Stockholders if the over-allotment option is not exercised by the Underwriters)
for an aggregate purchase price of $25,000, or $0.012 per share, prior to the consummation of the Public Offering; (iv) “Initial Stockholders”
shall mean the Sponsor, the Representative, and any Insider that holds Founder Shares; (v) “Private Placement Shares”
shall mean the 242,600 shares of Common Stock comprising the Private Placement Units; (vi) “Private Placement Units”
shall mean the 242,600 units to be purchased by the Sponsor, each comprised of one share of Common Stock, and one-half of one warrant
to purchase one share of Common Stock, or purchase price of $10.00 per Private Placement Unit, in a private placement that shall occur
simultaneously with the consummation of the Public Offering; (vii) “Private Placement Warrants”
shall mean the Warrants to purchase up to 121,300 shares of Common Stock comprising the Private Placement Units; (viii) “Public Stockholders”
shall mean the holders of securities issued in the Public Offering; (ix) “Trust Account”
shall mean the trust fund into which a portion of the net proceeds of the Public Offering and the sale of the Private Placement Units
shall be deposited; and (x) “Transfer” shall mean the (a) sale of, offer to sell, contract or agreement
to sell, hypothecate, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly,
or establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call equivalent position within
the meaning of Section 16 of the Exchange Act, and the rules and regulations of the Commission promulgated thereunder with
respect to, any security, (b) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of any security, whether any such transaction is to be settled by delivery of such securities, in
cash or otherwise, or (c) public announcement of any intention to effect any transaction specified in clause (a) or (b).

 

13.
The Company will undertake commercially reasonable efforts to maintain an insurance policy or policies providing directors’ and
officers’ liability insurance, and each Director shall be covered by such policy or policies, in accordance with its or their terms,
to the maximum extent of the coverage available for any of the Company’s directors or officers.

 

14.
This Letter Agreement constitutes the entire agreement and understanding of the parties hereto in respect of the subject matter hereof
and supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent
they relate in any way to the subject matter hereof or the transactions contemplated hereby. This Letter Agreement may not be changed,
amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument
executed by all parties hereto.

 

15.
No party hereto may assign either this Letter Agreement or any of its rights, interests, or obligations hereunder without the prior written
consent of the other parties. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate
to transfer or assign any interest or title to the purported assignee. This Letter Agreement shall be binding on the Sponsor, the Representative,
and each Insider and their respective successors, heirs and assigns and permitted transferees.

 

    5

    

    

 

16.
Nothing in this Letter Agreement shall be construed to confer upon, or give to, any person or corporation other than the parties hereto
any right, remedy or claim under or by reason of this Letter Agreement or of any covenant, condition, stipulation, promise or agreement
hereof. All covenants, conditions, stipulations, promises and agreements contained in this Letter Agreement shall be for the sole and
exclusive benefit of the parties hereto and their successors, heirs, personal representatives and assigns and permitted transferees.

 

17.
This Letter Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

18.
This Letter Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect
the validity or enforceability of this Letter Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid
or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Letter Agreement a provision
as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

19.
This Letter Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving
effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The parties
hereto (i) all agree that any action, proceeding, claim or dispute arising out of, or relating in any way to, this Letter Agreement
shall be brought and enforced in the courts of New York City, in the State of New York, and irrevocably submit to such jurisdiction and
venue, which jurisdiction and venue shall be exclusive and (ii) waive any objection to such exclusive jurisdiction and venue or
that such courts represent an inconvenient forum.

 

20.
Any notice, consent or request to be given in connection with any of the terms or provisions of this Letter Agreement shall be in writing
and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery
or facsimile transmission.

 

21.
This Letter Agreement shall terminate on the earlier of (i) the expiration of the Lock-up Periods or (ii) the liquidation of
the Company; provided, however, that this Letter Agreement shall earlier terminate in the event that the Public Offering is not consummated
and closed by [_], 2021; provided further that paragraph 4 of this Letter Agreement shall survive such liquidation. 

 

22.
The Company, the Sponsor, and each Insider hereby acknowledges and agrees that the Underwriters are third party beneficiaries of this
Letter Agreement.

 

[Signature
Page Follows]

 

    6

    

    

 

	 	Sincerely, 
	 	 
	 	LARKSPUR HEALTH LLC
	 	 
	 	By:	 
	 	Name: 	Daniel J. O’Connor
	 	Title: 	Manager
	 	 
	 	A.G.P./ALLIANCE GLOBAL PARTNERS
	 	 
	 	By:	 
	 	Name: 	 
	 	Title: 	 
	 	 
	 	 
	 	DANIEL J. O’CONNOR
	 	 
	 	 
	 	DAVID S. BRIONES
	 	 
	 	 
	 	RAJ MEHRA
	 	 
	 	 
	 	GREGORY SKALICKY
	 	 
	 	 
	 	CHRISTOPHER TWITTY

 

	Acknowledged and Agreed:	 
	 	 
	LARKSPUR HEALTH ACQUISITION CORP. 	 
	 	 
	By:	 	 
	Name:   	Daniel J. O’Connor	 
	Title: 	Chief Executive Officer	 

 

 

[Signature
Page to Letter Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]